Oral Epithelial HIV Cell Line

Immortalized human oral epithelial cell line (iOECHHN) derived from a HIV+ (HAART naïve) subject.

Highlights:

  • Primary oral epithelial cells (POECs) transfected with lentiviral vectors carrying the SV40 T antigen allowing for permanent use of cells
  • Isolated from gingival tissue from a 47 year old HIV+ (HAART naive) subject

The oral epithelium is the most abudant structural tissue lining the oral mucosa, and is an important factor in fighting infectious microorganisms. Human immunodeficiency virus (HIV) is a lentivirus that causes the acquired immunodeficienty syndrome (AIDS). Due to the availability of highly active-retroviral therapy (HAART), HIV+ infected patients are living longer. HIV infected subjects on HAART are suspectible to comorboid microbial infections in the oral cavity.

From the laboratory of Aaron Weinberg, DMD, PhD and Santosh K. Ghosh, PhD, Case Western Reserve University.

The Investigator's Annexe Part of The Investigator's Annexe program.

Catalog Number Product Size AVAILABILITY Price Qty
ECW001
Oral Epithelial HIV Cell Line, 1 Vial
1 vial In stock
Price: $799.00
Contact us for details.

This product is for sale to Nonprofit customers only. For profit customers, please Contact Us for more information.

Specifications
Product Type: Cell Line
Name: iOECHHN
Cell Type: Oral Epithelial Cells
Organism: Human
Accession ID: CVCL_0P76
Morphology: Epithelial
Biosafety Level: 1
Subculturing: 1 week
Growth Conditions: Epilife+HKGS+1% PSG
Cryopreservation: 10% DMSO
Source: Gingival Tissue
Storage: Liquid nitrogen
Shipped: Dry ice
Provider
From the laboratory of Aaron Weinberg, DMD, PhD and Santosh K. Ghosh, PhD, Case Western Reserve University.
References
  1. Ghosh SK, McCormick TS, Eapen BL, Yohannes E, Chance MR, Weinberg A. Comparison of epigenetic profiles of human oral epithelial cells from HIV-positive (on HAART) and HIV-negative subjects. Epigenetics. 2013 Jul;8(7):703-9.

If you publish research with this product, please let us know so we can cite your paper.

 
Loading...
Loading...